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OVERVIEW OF ENTEROHEPATIC BILE ACID TRANSPORTERS 
 
 
Bile acids are physiological detergents that promote absorption and excretion of cholesterol, 
lipids, and other hydrophobic compounds in the liver and intestine (1). Bile acids are 
synthesized de novo in the liver through cholesterol catabolism and stored in the gall 
bladder, from which they are postprandially released into the intestine. From the ileum bile 
acids are returned back to the liver via portal blood. The enterohepatic circulation of bile 
acids is a highly efficient process in healthy individuals, and is of crucial importance for the 
maintenance of bile flow and hepatic secretory function. The recycling of bile acids between 
the liver and intestine is mediated by specific transporter proteins, expressed at the plasma 
membranes of hepatocytes and enterocytes in a polarized manner (2). 
The chief transporter responsible for the excretion of bile acids from hepatocytes into 
bile canaliculi is the bile salt export pump (BSEP, ABCB11) (3), which belongs to the ATP-
binding cassette (ABC) transporter family (4). Whereas BSEP exports monovalent bile 
acids, another ABC transporter at the canalicular membrane of hepatocytes, multidrug 
resistance-asscoiated protein 2 (MRP2, ABCC2), excretes divalent and 
sulphated/glucuronidated bile acids into bile (5). While bile acids are the most prominent 
(60-70%) components of bile, it also contains phospholipids and cholesterol, which form 
mixed micelles with the bile acids. The latter two components are translocated into bile by 
further canalicular ABC family transporters, namely the multidrug resistance protein 3 
(MDR3, ABCB4) and the heterodimeric ABCG5/ABCG8, respectively (4). 
After their passage to the intestinal lumen, bile acids are taken up into ileocytes via the 
apical sodium-dependent transporter (ASBT, SLC10A2) (6), the activity of which is coupled 
with cotransport of sodium. At the basolateral membranes of ileal enterocytes, bile acids are 
extruded into portal blood by the organic solute transporter heterodimer OST/OST (7). 
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The larger subunit OST contains seven predicted transmembrane domains, whereas OST 
has a single membrane-spanning domain. Coexpression of OST and OST polypeptides is 
required for correct localization of the heterodimer at the cell membrane and for transport 
activity. In agreement with its role as the intestinal bile acid efflux transporter, relative 
distribution of the OST/OST heterodimer along the intestinal tract is similar to that of the 
bile acid uptake system ASBT. 
To complete their enterohepatic circulation, bile acids are finally taken up from 
sinusoidal blood back into parenchymal hepatocytes by transport proteins located at the 
basolateral membrane. The chief hepatic uptake system for bile acids is the sodium 
taurocholate cotransporting polypeptide (NTCP, SLC10A1) (6), which belongs to the same 
SLC10 transporter family as ASBT. A member of the organic anion transporter family 
located at the basolateral membrane, OATP1B1 (SLCO1B1), may to a smaller degree also 
contribute to hepatic bile acid extraction from portal blood in a sodium-independent manner 
(8). 
 
 
INDUCTION OF HUMAN BILE ACID EFFLUX TRANSPORTERS BY THE BILE 
ACID RECEPTOR FXR 
 
Due to their detergent properties, bile acids can be intrinsically toxic to cells, hence their 
intracellular concentration must be tightly controlled. In addition to their role as 
physiological detergents, bile acids can act as signalling molecules and homeostatic 
regulators of their own transport and metabolism within the enterohepatic circulation. By 
controlling their own cellular uptake or efflux via regulation of the expression levels of bile 
acid transporter genes, bile acids can adjust their own intracellular concentrations.  
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The chief sensor of intracellular bile acid levels and the main executor of bile acid-
induced transcriptional programmes is a transcription factor of the nuclear receptor family, 
namely the farnesoid X receptor (FXR) (9). Bile acids directly interact with, and function as 
agonists ligands of, the ligand-binding domain of FXR. In accordance with its function as 
the bile acid receptor, FXR is most abundantly expressed in the tissues commonly exposed 
to bile acids: liver, intestine, and kidneys. The preferred DNA-binding sequence for FXR 
within its target promoters is the so-called "inverted repeat-1" motif (IR-1, inverted 
hexameric repeat separated by one base pair) (10), to which FXR binds as a heterodimer 
with another nuclear receptor, namely the retinoid X receptor (RXR). 
In response to bile acids FXR stimulates BSEP expression via direct interaction of 
FXR-RXR heterodimers with an IR-1 element located in the proximal promoter of the 
ABCB11 gene (11-13). Thus, excessive levels of bile acids lead to stimulation of their own 
hepatocanalicular clearance. The FXR-RXR response element is conserved between the 
human and rodent ABCB11/Abcb11 promoters, in support of its functional importance. 
Similarly to the ABCB11 gene, expression of the ABCC2 gene encoding MRP2, the 
transporter for divalent bile acids at the canalicular membrane, can also be activated by bile 
acids and FXR (14). In the case of the ABCC2 promoter, FXR transactivates through an 
atypical "everted repeat-8" (ER-8) motif. In addition to the canalicular bile acid transporter 
genes, bile acid-activated FXR can induce the expression of the ABCB4 gene encoding 
MDR3, the phospholipid transporter at the canalicular membrane of hepatocytes (15). Thus, 
bile acids, by activating FXR, induce the excretion of both bile acids (BSEP, MRP2) and 
phospholipids (MDR3) into bile in a coordinated manner. 
In an analogous manner to the ABCB11 gene, expression of the two genes encoding 
the heterodimeric bile acid efflux system in the intestine, OST/OST are induced by bile 
acids through direct binding of FXR-RXR heterodimers to the two human OST promoters 
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(16,17). While the regulatory regions of the OST promoter appear to harbour a single IR-1-
like motif that mediates binding by FXR-RXR, the human OST promoter contains two 
adjacent IR-1-like FXR response elements, both of which are functional and required for 
maximal induction by bile acids. In addition to established cell lines, both OST and OST 
gene expression can be induced by bile acids in short-term tissue culture of human ileal 
biopsies. Further physiological evidence in support of the induction of OST gene expression 
by bile acids is provided by a study showing that both mRNA and protein levels of 
OSTand OST are increased in cholestatic liver tissue of patients suffering from primary 
biliary cirrhosis (18).  
 
 
SUPPRESSION OF HUMAN BILE ACID UPTAKE TRANSPORTERS BY THE 
BILE ACID RECEPTOR FXR 
 
In keeping with the model that the bile acid sensor FXR elicits hepatoprotective 
mechanisms aiming at decreasing the intracellular bile acid load, activation of FXR by 
elevated intracellular levels of bile acids also results in downregulation of  genes encoding 
enterohepatic bile acid uptake sytems. In rodent models of cholestasis, expression of the 
hepatic bile acid uptake system Ntcp is suppressed at both the protein and mRNA level (19). 
Importantly, certain human cholestatic states, such as advanced stage primary biliary 
cirrhosis and cholestatic alcoholic hepatitis, are also associated with reduced NTCP 
expression (20,21). We have recently shown that the mechanism of down-regulation of the 
human SLC10A1 gene, encoding NTCP, in response to bile acids involves a bile acid-
inducible repressor of the nuclear receptor family, known as the small heterodimer partner 
(SHP) (22). SHP is  an unusual member of the nuclear receptor family, since it lacks any 
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direct DNA-binding activity (23). The promoter of the SHP gene is itself a target for 
transcriptional activation by ligand-bound FXR (24,25). Thus, in response to elevated bile 
acids, FXR-induced SHP negatively targets a DNA-binding transactivator of the SLC10A1 
gene, the glucocorticoid receptor (GR). The negative interference of GR by SHP involves 
direct interaction between the two proteins, which may block the recruitment of the 
transcriptional coactivator PGC-1to the human SLC10A1 promoter (22,26). 
The bile acid-FXR-SHP cascade also suppresses transcription of the SLCO1B1 gene 
encoding the OATP1B1 transporter, which may contribute to bile acid uptake at the 
basolateral membranes of hepatocytes (27). The molecular target of SLCO1B1 down-
regulation by bile acids is the liver-enriched transcription factor HNF-1, which is a strong 
DNA-binding transactivator of the SLCO1B1 promoter. The regulatory region of the HNF-
1 gene itself contains a DNA-binding motif for the nuclear receptor HNF-, the 
transcriptional activity of which is targeted for negative interference by the SHP protein.  
HNF-4 also functions as a common transactivator of hepatic drug transporter genes, 
such as the human SLC22A1 and SLC22A7 genes, which encode polyspecific drug 
transporters OCT1 and OAT2, respectively, both located at the basolateral membranes of 
hepatocytes (28,29). The bile acid-induced transcriptional repressor SHP interferes with 
transactivation by HNF-4 in the context of both the SLC22A1 and SLC22A7 genes. Thus, 
in conditions of elevated intracellular bile acid concentrations, the expression of two major 
human drug uptake systems at the basolateral hepatic membranes may be reduced. This 
could restrict the amount of drugs xenobiotics that enter hepatocytes, when intracellular 
levels of toxic bile acids are already elevated.  
In an analogous manner to NTCP, bile acids also suppress the expression of the 
intestinal bile acid uptake system ASBT, another member of the SLC10 transporter family 
in humans (30). In agreement with this, SLC10A2 gene expression has been reported to be 
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reduced in patients with obstructive cholestasis (31). Similarly to the SLC10A1 gene, the 
transactivator protein GR is targeted for negative interference by the bile acid-induced 
transcriptional repressor SHP on the SLC10A2 promoter (22,32). Interestingly, while both 
the SLC10A1 and SLC10A2 genes are transactivated by GR, the relative locations and 
sequence configurations of the GR response elements within the two SLC10 promoters are 
not conserved 
 
 
CONCLUDING REMARKS 
 
The function of enterohepatic bile acid transporters is vital for the maintenance of bile acid 
homeostasis in healthy individuals. Furthermore, the importance of these transporter 
proteins for hepatic and intestinal function is emphasized by recent demonstrations that 
either hereditary or acquired disturbances in the activity and/or expression of bile acid 
transporters are associated with cholestatic diseases. Bile acids are capable of regulating the 
expression of transporters that mediate the enterohepatic circulation of both bile acids and 
drugs via complex feedforward and feedback mechanisms. The main orchestrator of these 
transcriptional circuits is the nuclear receptor for bile acids,  FXR, which controls the 
expression levels of genes encoding the major bile acid transporters at all membrane 
domains of enterohepatic circulation.  
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